S-1/Leucovorin (SL) Versus sLV5FU2 as the First-line Treatment for Elderly Patients With Colorectal Cancer

NCT ID: NCT01193452

Last Updated: 2010-09-02

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-08-31
• Study Completion Date: 2012-02-29

Brief Summary

This phase II trial on the assumption that S-1 combined with Leucovorin may have better efficacy and safety than simplified 5-FU/LV infusion therapy in elderly patients with advanced colorectal cancer.

Detailed Description

This is a randomized phase Ⅱ study, in which S-1 is used in combination with leucovorin in elderly patients with advanced colorectal cancer as first-line treatment,comparing with sLV5FU2 therapy. The aim of this study is to determine the efficacy and safety of S-1/LV in elderly patients in the first-line setting. The other secondary endpoints are progression free survival,overall survival, and quality of life are also evaluated.

Conditions

Colorectal Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

S-1/LV

S-1 combined with Leucovorin

Group Type: EXPERIMENTAL

S-1, Leucovorin

Intervention Type: DRUG

S-1 :

The initial dosage of S-1 is determined by the body surface area:

Surface area: 1.25-1.5 m2 : 50mg twice per day;upper than 1.5 m2 : 60mg twice per day

Leucovorin:

25mg twice per day po.

The treatment is given for one week,and no chemotherapy is given for the following one week.

sLV5FU2

5-FU/LV infusion

Group Type: ACTIVE_COMPARATOR

leucovorin, 5-fluorouracil

Intervention Type: DRUG

leucovorin: 400mg/m2 intravenous infusion d1;

5-fluorouracil: 400mg/m2 intravenous push,d1; 2400mg/m2 continuous intravenous infusion for 46 hours

repeat every 2 weeks

Interventions

S-1, Leucovorin

S-1 :

The initial dosage of S-1 is determined by the body surface area:

Surface area: 1.25-1.5 m2 : 50mg twice per day;upper than 1.5 m2 : 60mg twice per day

Leucovorin:

25mg twice per day po.

The treatment is given for one week,and no chemotherapy is given for the following one week.

Intervention Type: DRUG

leucovorin, 5-fluorouracil

leucovorin: 400mg/m2 intravenous infusion d1;

5-fluorouracil: 400mg/m2 intravenous push,d1; 2400mg/m2 continuous intravenous infusion for 46 hours

repeat every 2 weeks

Intervention Type: DRUG

Other Intervention Names

chemotherapy; chemotherapy

Eligibility Criteria

Inclusion Criteria

• Signed written informed consent
• Oral medication is acceptable
• Histologically confirmed colorectal carcinoma
• Male or female ≥ 65 years of age
• No prior chemotherapy,radiotherapy,target therapy and immunotherapy, except adjuvant chemotherapy with an interval of ≥ 180 days)
• Presence of at least one target lesion measurable by CT scan or MRI,within 15 days prior to trial
• The lab values within 2 weeks prior to trial should meet:

PLT ≥7.5*10^4/mm3 ANC≥2000/mm3 HB≥100g/L Total bilirubin < upper limit of normal level ALT/AST/ALP < 2.5 x UNL (<5 x UNL for patients with liver or bone metastasis) Serum creatinine < UNL

• Performance status (ECOG) 0~1
• Life expectation longer than 90 days

Exclusion Criteria

• Allergy to S-1,fluorouracil or leucovorin
• Any investigational agent(s) within 4 weeks prior to entry
• Previous or currently exposure to certain drugs which are proved to have influence on blood drug concentration
• Active infection
• Severe organ failures or diseases, including: intestinal obstruction, pulmonary fibrosis, uncontrolled diabetes mellitus,clinically relevant coronary disease, cardiovascular disorder or myocardial infarction,renal or liver failure, severe psychiatric illness,cerebral vascular disease and sever GI ulcer which need blood infusion.
• Uncontrolled hydrothorax,ascites and hydropericardium
• Multiple bone metastatic lesions
• Brain metastases
• Chronic diarrhea or digestive disfunction
• Previous malignancy (except colorectal cancer, history of basal cell carcinoma of skin or pre-invasive carcinoma of the cervix with adequate treatment)
• Strong willingness to receive surgery or highly potential to have intestinal obstruction which may need surgery intervention
• Other conditions that primary investigate or investigator consider to be unsuitable for the trial

• Minimum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Fudan University

OTHER

Sponsor Role: lead

Responsible Party

Fudan University Shanghai Cancer Center

Principal Investigators

Jin Li, MD,PhD

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Locations

Jin Li'

Shanghai, Shanghai Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Jin Li, MD,PhD

Role: CONTACT

64175590 ext. 5100

Wenhua Li, MS

Role: CONTACT

whliiris@hotmail.com

64175590 ext. 8900

Facility Contacts

Jin Li, MD,PhD

Role: primary

8621 64175590 ext. 5100

Wenhua Li, MS

Role: backup

whliiris@hotmail.com

862164175590 ext. 8900

Other Identifiers

SL-eCRC

Identifier Type: -

Identifier Source: org_study_id